Product recall

Article

McNeil-PPC Inc, a division of Johnson & Johnson, is recalling all Glacier Mint and Bubble Blast flavors of a child-friendly Listerine mouthwash, called Agent Cool Blue. The mouthwash colors the plaque on teeth, allowing for easier brushing.

McNeil-PPC Inc, a division of Johnson & Johnson, is recalling all Glacier Mint and Bubble Blast flavors of a child-friendly Listerine mouthwash, called Agent Cool Blue. The mouthwash colors the plaque on teeth, allowing for easier brushing.

The preservatives in the mouthwashes were not adequate against certain organisms. Only those with weakened or suppressed immune systems are thought to be at risk. For more recall information, call 1-888-222-0249 or visit www.agentcoolblue.com

Related Videos
Angela Nash, PhD, APRN, CPNP-PC, PMHS | Image credit: UTHealth Houston
Allison Scott, DNP, CPNP-PC, IBCLC
Joanne M. Howard, MSN, MA, RN, CPNP-PC, PMHS & Anne Craig, MSN, RN, CPNP-PC
Juanita Mora, MD
Natasha Hoyte, MPH, CPNP-PC
Lauren Flagg
Venous thromboembolism, Heparin-induced thrombocytopenia, and direct oral anticoagulants | Image credit: Contemporary Pediatrics
Jessica Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN
Sally Humphrey, DNP, APRN, CPNP-PC | Image Credit: Contemporary Pediatrics
Related Content
Study: Neonatal outcomes not associated with hyperoxygenation use | Image Credit: © Coka - © Coka - stock.adobe.com.

Study: Neonatal outcomes not associated with hyperoxygenation use

April 25th 2024
Article

Research in AJOG: Maternal hyperoxygenation doesn't boost neonatal Apgar scores in pathologic fetal heart rate tracing, showing no FiO2 benefit.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
Perry Roy, MD | Image Credit: Carolina Attention Specialists

Incorporating objective testing to add value to an ADHD diagnosis

April 25th 2024
Article

Perry Roy, MD, explains how an FDA-cleared objective test can assist in an ADHD diagnosis.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
FDA approves tovorafenib for most common form of childhood brain tumor | Image Credit: © Calin - © Calin - stock.adobe.com.

FDA approves tovorafenib for most common form of childhood brain tumor

April 24th 2024
Article

This decision from the federal agency marks the first FDA approval of a systemic therapy to treat patients with pediatric LGG with BRAF rearrangements, including fusions.

First radioactive drug approved for patients 12 years and up with SSTR-positive GEP-NETs | Image Credit: © Calin - © Calin - stock.adobe.com.

First radioactive drug approved for patients 12 years and up with SSTR-positive GEP-NETs

April 23rd 2024
Article

The FDA has approved lutetium Lu 177 dotatate for pediatric patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

© 2024 MJH Life Sciences

All rights reserved.